Pharmaceutical - Asia-Pacific

Filter

Current filters:

Asia-Pacific

Popular Filters

76 to 100 of 676 results

2014 to be transition year for Japan pharma

2014 to be transition year for Japan pharma

11-02-2014

2014 will be marked as a transition year for the Japanese Pharma industry – but the year is bound to…

Asia-PacificPharmaceuticalPricingRegulationResearch

Hisamitsu announces positive Phase II results for Parkinson’s disease drug

10-02-2014

Japanese drugmaker Hisamitsu Pharmaceutical’s has announced the results of a Phase II clinical study…

Asia-PacificHisamitsu PharmaLevodopaNeurologicalPharmaceuticalResearch

Kinex and PharmaEssentia expand drug development partnership

06-02-2014

Privately-held USA-based Kinex Pharmaceuticals and Taiwan’s PharmaEssentia say they have signed a new…

Asia-PacificKinex PharmaceuticalsLicensingOncologyOratecanOraxolPharmaceuticalPharmaEssentia

AbbVie to spend $320 million to establish Singapore manufacturing presence

AbbVie to spend $320 million to establish Singapore manufacturing presence

06-02-2014

US drugmaker AbbVie says it plans to invest $320 million to establish operations in Singapore for small…

AbbVieAsia-PacificImmunologicalsOncologyPharmaceuticalProduction

Australian industry calls on government to save the PBS

Australian industry calls on government to save the PBS

06-02-2014

Medicines Australia has called on the Australian government to save the Pharmaceutical Benefits Scheme…

Asia-PacificAustraliaHealthcarePatentsPharmaceuticalPolitics

Regulatory update on Indian clinical research approval timelines

04-02-2014

The Drug Controller General of India (DCGI) has provided written confirmation to the pharmaceutical industry…

Asia-PacificIndiaPharmaceuticalRegulationResearch

Sagent Pharma sets up research center in China

04-02-2014

US specialty drug firm Sagent Pharmaceuticals (Nasdaq: SGNT), which has a specific emphasis on the injectable…

Asia-PacificChinaPharmaceuticalResearchSagent Pharmaceuticals

Ferrer links with Ildong and Ergomed for lorediplon development

03-02-2014

Privately-held Spanish drugmaker Ferrer has executed two agreements, one with South Korea’s Ildong…

Asia-PacificErgomed Clinical ResearchFerrer InternacionalIldong PharmaLicensinglorediplonNeurologicalPharmaceuticalResearch

Pharma multinationals facing more pricing problems in India

Pharma multinationals facing more pricing problems in India

03-02-2014

Even as a battle royal appears to be brewing between India's drug price regulator, the National Pharma…

Asia-PacificAstraZenecaFinancialGlaxoSmithKlineIndiaNovartisPfizerPharmaceuticalPricing

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

31-01-2014

Belgium-based VIB, a non-profit research institute in life sciences, and the Center for Drug Design and…

Asia-PacificAstraZenecaIndiaInflammatory diseasesOncologyPharmaceuticalResearchTropical diseases

UCB and Biogen sign Asian license agreement for MS drugs

UCB and Biogen sign Asian license agreement for MS drugs

30-01-2014

Belgian drugmaker UCB and US biotech firm Biogen Idec have signed exclusive agreements granting UCB the…

AlprolixAsia-PacificBiogen IdecBiotechnologyEloctateLicensingNeurologicalPharmaceuticalTecfideraUCB

Chinese health professionals' conduct to be regulated

29-01-2014

China's National Health and Family Planning Commission this week issued a draft regulation on health…

Asia-PacificChinaPharmaceuticalRegulation

Ariad Pharma plans commercialization of Iclusig in Australia

Ariad Pharma plans commercialization of Iclusig in Australia

28-01-2014

US specialty pharma firm Ariad Pharmaceuticals has signed an agreement with Specialised Therapeutics…

Ariad PharmaceuticalsAsia-PacificAustraliaIclusigLicensingOncologyPharmaceuticalSpecialised Therapeutics Australia

Cadila pulls out of operations in Japan

Cadila pulls out of operations in Japan

28-01-2014

One of India’s largest pharmaceutical companies, Cadila Healthcare (also operating as Zydus Cadila),…

Asia-PacificFinancialIndiaPharmaceuticalZydus Cadila

India loses its attraction for pharma clinical trials, as domestic regulations tighten

India loses its attraction for pharma clinical trials, as domestic regulations tighten

27-01-2014

Considered a global clinical trial hub three years ago, India has suffered a series of setbacks, with…

Asia-PacificBioconIndiaPharmaceuticalPiramal HealthcareRegulationResearch

Advaxis out-licenses ADXS-HPV to Biocon for emerging markets

Advaxis out-licenses ADXS-HPV to Biocon for emerging markets

23-01-2014

Indian biotech firm Biocon has entered into an exclusive licensing agreement for US cancer drug developer…

AdvaxisADXS-HPVAsia-PacificBioconIndiaLicensingOncologyPharmaceuticalWomen's Health

Norgine and Kissei’s Savene approved in Japan

21-01-2014

Independent Dutch firm Norgine and its Japanese partner Kissei Pharmaceutical received approval from…

Asia-PacificKissei PharmaceuticalNorgineOncologyPharmaceuticalRegulationSavene

Japanese approval for Bayer’s riociguat for CTEPH

Japanese approval for Bayer’s riociguat for CTEPH

20-01-2014

German pharma major Bayer has received approval from the Ministry of Health, Labor and Welfare for riociguat,…

AdempasAsia-PacificBayerPharmaceuticalRegulationRespiratory and Pulmonaryriociguat

Growing Indian pharma market provides incentives for foreign acquisitions

20-01-2014

A recent IMS Institute for Healthcare Informatics global study has revealed that greater access to medicines…

Asia-PacificIndiaMarkets & MarketingMergers & AcquisitionsPharmaceutical

Astellas gains Japanese clearance for diabetes drug Suglat

Astellas gains Japanese clearance for diabetes drug Suglat

20-01-2014

Japanese drug major Astellas Pharma has obtained the marketing approval of selective SGLT2 inhibitor…

Asia-PacificAstellas PharmaDiabetesipragliflozinKotobuki PharmaceuticalMerck & CoPharmaceuticalRegulationSuglat

Indian government proceeds with FDI policy, despite warnings

Indian government proceeds with FDI policy, despite warnings

20-01-2014

Overlooking concerns about the scarcity of generic drugs in the domestic market given the spate of multinationals…

Asia-PacificIndiaMergers & AcquisitionsPharmaceuticalPolitics

Tivicay set to become leading HIV treatment by 2016

Tivicay set to become leading HIV treatment by 2016

15-01-2014

Antiretroviral drug Tivicay (dolutegravir) is set to become the leading integrase inhibitor for the treatment…

Anti-viralsAsia-PacificEuropeIsentressJanssenMarkets & MarketingMerck & CoPharmaceuticalPrezistaTivicayUSAViiV Healthcare

76 to 100 of 676 results

Back to top